Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
CRISPR Therapeutics AG (CRSP) had Free Cash Flow per Share of $-2.93 for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$12.67M |
|
$-111.44M |
|
-- |
|
$12.67M |
|
$142.71M |
|
$-130.04M |
|
$18.68M |
|
$-111.36M |
|
$-111.36M |
|
$-111.44M |
|
$-111.44M |
|
$-111.44M |
|
$-111.44M |
|
$-130.04M |
|
$-125.81M |
|
96.74M |
|
96.74M |
|
$-1.15 |
|
$-1.15 |
|
| Balance Sheet Financials | |
$2.29B |
|
$104.30M |
|
$271.33M |
|
$2.56B |
|
$140.96M |
|
$586.93M |
|
$767.38M |
|
$908.34M |
|
$1.65B |
|
$1.65B |
|
$1.65B |
|
96.86M |
|
| Cash Flow Statement Financials | |
$-282.08M |
|
$-480.49M |
|
$603.54M |
|
$359.08M |
|
$200.03M |
|
$-159.04M |
|
$51.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.21 |
|
-- |
|
-- |
|
0.26 |
|
0.36 |
|
100.00% |
|
-1026.48% |
|
-1026.48% |
|
-- |
|
-879.02% |
|
-879.60% |
|
$-283.64M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-6.76% |
|
-6.76% |
|
-4.36% |
|
-4.99% |
|
$17.02 |
|
|
Free Cash Flow per Share |
$-2.93 |
$-2.92 |
|